Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Users Online: 413 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

 Table of Contents  
EDITORIAL
Year : 2015  |  Volume : 5  |  Issue : 2  |  Page : 82  

Real world data: Additional source for making clinical decisions


Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

Date of Web Publication18-May-2015

Correspondence Address:
Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2229-516X.157148

Rights and Permissions

How to cite this article:
Mahajan R. Real world data: Additional source for making clinical decisions. Int J App Basic Med Res 2015;5:82

How to cite this URL:
Mahajan R. Real world data: Additional source for making clinical decisions. Int J App Basic Med Res [serial online] 2015 [cited 2020 May 24];5:82. Available from: http://www.ijabmr.org/text.asp?2015/5/2/82/157148

International Society for Pharmacoeconomics and Outcome Research has defined real-world data as everything that goes beyond what is normally collected in the phase III clinical trials program in terms of efficacy. It is also conveniently labeled as anything that is not interventional. [1]

Though randomized clinical trials (RCTs) are considered gold standard for establishing efficacy; [2] in general, RCTs use a standardized therapy in a selected group of patients and are typically restricted to evaluating specific discrete interventions one at a time. [3] As such, RCTs fail to assess complex interactions within a study arm, fail to establish continuous relationship and fail to elucidate if the benefits/harms of a treatment are drug specific or mechanistic. As a result, traditional RCTs focuses more on evaluating the efficacy of simple therapies and less on the delivery of care, and it is said that RCTs have internal validity but not external validity. For assessing effectiveness of combinations and for evaluating all these issues in RCTs, many study arms will be required. For example, it would take 32 different study arms to examine all the possible combinations of just five treatments; thus making the costs conduct RCTs that evaluate all these issues prohibitive. [4]

This is where real-world data has a role to play. Many health-care decision makers are developing policies that integrate evidence from different sources. It is importantly being accepted that other sources of data can contribute in important ways to the evidence base (e.g., demonstrating how a drug works in populations not studied in the trial, or relative to another drug not included in the study). [5]

As such in real-world studies, the actual care that patients receive in clinics is recorded. Rather than having strict inclusion and exclusion criteria, all the patients have to be treated, including those with co-morbidities. Such studies generate long term efficacy and safety data along with economic assessment under pragmatic conditions. Moreover, it is possible to compare multiple interventions in such studies. [6] Data source for real-world data can be-supplements to traditional registration RCTs; large, simple trials (known as pragmatic clinical trials); registries; administrative data; health surveys; and electronic health records and medical chart reviews. [5]

Though there are number of issues with collection of real-world data like lack of good quality and sufficiently representative databases in many countries, incomplete databases, presence of many asymptomatic cases in real world (an issue with retrospective observation of data), more chances of bias and confounding in prospective real-world studies (as it is without randomization) etc., real-world data has an important role to play in the evaluation of epidemiology and burden of disease, treatment patterns, compliance, persistence, and health outcomes of different treatments. [1]



 
   References Top

1.
Annemans L, Aristides M, Kubin M. Real Life Data: A Growing Need. ISPOR Connections. Available from: http://www.ispor.org/news/articles/oct07/rld.asp. [Last cited on 2014 Sep 12].  Back to cited text no. 1
    
2.
Stanley K. Design of randomized controlled trials. Circulation 2007;115:1164-9.  Back to cited text no. 2
    
3.
Stanley K. Evaluation of randomized controlled trials. Circulation 2007;115:1819-22.  Back to cited text no. 3
    
4.
Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: The role of effectiveness studies in evaluating cardiovascular therapies. Circulation 2008;118:1294-303.  Back to cited text no. 4
    
5.
Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report. Value Health 2007;10:326-35.  Back to cited text no. 5
    
6.
Ziemssen T. The real-world evidence for oral therapies in RRMS. Medsacpe education. Available from: http://www.medscape.org/viewarticle/830506_slide. [Last cited on 2014 Sep 12].  Back to cited text no. 6
    



This article has been cited by
1 Real-world evidence of subcutaneous allergoid immunotherapy in house dust mite-induced allergic rhinitis and asthma
Marek Jutel,Bernd Brüggenjürgen,Hartmut Richter,Christian Vogelberg
Allergy. 2020;
[Pubmed] | [DOI]
2 Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative
Yael A. Leshem,Joanne R. Chalmers,Christian Apfelbacher,Masutaka Furue,Louise A.A. Gerbens,Cecilia A.C. Prinsen,Jochen Schmitt,Phyllis I. Spuls,Kim S. Thomas,Hywel C. Williams,Eric L. Simpson
Journal of the American Academy of Dermatology. 2020;
[Pubmed] | [DOI]
3 Improving Population Pharmacokinetics Through the Use of Genetic Algorithms
Mikhail Morozov,Ezequiel Nuske,Héctor Alejandro Serra
Journal of Pharmaceutical Innovation. 2020;
[Pubmed] | [DOI]
4 Trial designs using real-world data: The changing landscape of the regulatory approval process
Elodie Baumfeld Andre,Robert Reynolds,Patrick Caubel,Laurent Azoulay,Nancy A. Dreyer
Pharmacoepidemiology and Drug Safety. 2019;
[Pubmed] | [DOI]
5 Proceed with Caution When Using Real World Data and Real World Evidence
Hun-Sung Kim,Ju Han Kim
Journal of Korean Medical Science. 2019; 34(4)
[Pubmed] | [DOI]
6 Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data
Maria Lindh,Jonas Banefelt,Kathleen M Fox,Sara Hallberg,Ming-Hui Tai,Mats Eriksson,Guillermo Villa,Maria K Svensson,Yi Qian
European Heart Journal - Quality of Care and Clinical Outcomes. 2019;
[Pubmed] | [DOI]
7 Effectiveness of comprehensive traditional Korean Medicine treatment on quality of life, anorexia and cachexia of cancer patients: Retrospective chart review
Wonju Han,Eunji Lee,Gajin Han,Sang-hoon Yoon,Gajin Han,Jungtae Leem
Journal of Korean Medicine. 2019; 40(2): 119
[Pubmed] | [DOI]
8 Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome
Sabrina Chiara Cecere,Gaia Giannone,Vanda Salutari,Laura Arenare,Domenica Lorusso,Graziana Ronzino,Rossella Lauria,Gennaro Cormio,Claudia Carella,Paolo Scollo,Viola Ghizzoni,Francesco Raspagliesi,Marilena Di Napoli,Enrica Mazzoni,Claudia Marchetti,Alice Bergamini,Michele Orditura,Giorgio Valabrega,Giovanni Scambia,Giuseppa Maltese,Elisabetta De Matteis,Cinzia Cardalesi,Vera Loizzi,Serena Boccia,Emanuele Naglieri,Giuseppa Scandurra,Sandro Pignata
Gynecologic Oncology. 2019;
[Pubmed] | [DOI]
9 Responder Rates to Fampridine Differ between Clinical Subgroups of Ms Patients and Patient Reported Outcome Influences Treatment Decision Making
C.E.P. van Munster,L. Kaya,K.H. Lam,N.F. Kalkers,J. Killestein,B.M.J. Uitdehaag
Multiple Sclerosis and Related Disorders. 2019; : 101489
[Pubmed] | [DOI]
10 Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in “Real-World” Management of Type 2 Diabetes Mellitus: The G-FORCE Study
Luc Van Gaal,Michel P. Hermans,Evis Daci,Kris Denhaerynck,Lut De Meester,Karen MacDonald,Ivo Abraham,Stefaan Vancayzeele,Michael Maris
Diabetes Therapy. 2019;
[Pubmed] | [DOI]
11 Utility of real-world evidence for evaluating anti–vascular endothelial growth factor treatment of neovascular age-related macular degeneration
James Talks,Vincent Daien,Robert P. Finger,Bora Eldem,Taiji Sakamoto,José Augusto Cardillo,Paul Mitchell,Tien Yin Wong,Jean-François Korobelnik
Survey of Ophthalmology. 2019;
[Pubmed] | [DOI]
12 Immunotherapy with grass pollen tablets reduces medication dispensing for allergic rhinitis and asthma: A retrospective database study in France
Philippe Devillier,Mathieu Molimard,Xavier Ansolabehere,Isabelle Bardoulat,Nicolas Coulombel,Frédérique Maurel,Philippe Le Jeunne,Pascal Demoly
Allergy. 2019;
[Pubmed] | [DOI]
13 Sacubitril/Valsartan in Daily Clinical Practice
Lourdes Vicent,Alberto Esteban-Fernández,Manuel Gómez-Bueno,Javier De-Juan,Pablo Díez-Villanueva,Ángel Manuel Iniesta,Ana Ayesta,Hugo González-Saldívar,Antonio Rojas-González,Ramón Bover-Freire,Diego Iglesias,Marcos García-Aguado,Jesús A. Perea-Egido,Manuel Martínez-Sellés
Journal of Cardiovascular Pharmacology. 2019; 73(2): 118
[Pubmed] | [DOI]
14 Do current approaches to assessing therapy related adverse events align with the needs of long-term cancer patients and survivors?
Syril D. Pettit,Rebecca Kirch
Cardio-Oncology. 2018; 4(1)
[Pubmed] | [DOI]
15 The positive impacts of Real-World Data on the challenges facing the evolution of biopharma
John Wise,Angeli Möller,David Christie,Dipak Kalra,Elia Brodsky,Evelina Georgieva,Greg Jones,Ian Smith,Lars Greiffenberg,Marie McCarthy,Michael Arend,Olivier Luttringer,Sebastian Kloss,Steve Arlington
Drug Discovery Today. 2018;
[Pubmed] | [DOI]
16 Tertiary Care Experience of Sorafenib in the Treatment of Progressive Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Korean Multicenter Study
Mijin Kim,Tae Hyuk Kim,Dong Yeob Shin,Dong-Jun Lim,Eui Young Kim,Won Bae Kim,Jae Hoon Chung,YoungKee Shong,Bo Hyun Kim,Won Gu Kim
Thyroid. 2018;
[Pubmed] | [DOI]
17 Real-world experience with use of Antihemophilic Factor (Recombinant), PEGylated for prophylaxis in severe haemophilia A
A. L. Dunn,S. P. Ahuja,E. S. Mullins
Haemophilia. 2018;
[Pubmed] | [DOI]
18 A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials
José Miguel Rivera-Caravaca,María Asunción Esteve-Pastor,Francisco Marín,Mariano Valdés,Vicente Vicente,Vanessa Roldán,Gregory Y.H. Lip
Mayo Clinic Proceedings. 2018;
[Pubmed] | [DOI]
19 Fostering the exchange of real world data across different countries to answer primary care research questions: an UNLOCK study from the IPCRG
Liza Cragg,Siân Williams,Thys van der Molen,Mike Thomas,Jaime Correia de Sousa,Niels H. Chavannes
npj Primary Care Respiratory Medicine. 2018; 28(1)
[Pubmed] | [DOI]
20 Utilisation of real-world data from heart failure registries in OECD countries - A systematic review
Xiaoyang Du,Adina Khamitova,Mattias Kyhlstedt,Sun Sun,Mathilde Sengoelge
IJC Heart & Vasculature. 2018;
[Pubmed] | [DOI]
21 The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice
Giuseppe Toffoli,Federico Innocenti,Jerry Polesel,Elena De Mattia,Franca Sartor,Chiara Dalle Fratte,Fabrizio Ecca,Eva Dreussi,Elisa Palazzari,Michela Guardascione,Angela Buonadonna,Luisa Foltran,Marica Garziera,Alessia Bignucolo,Stefania Nobili,Enrico Mini,Adolfo Favaretto,Massimiliano Berretta,Mario DæAndrea,Antonino De Paoli,Rossana Roncato,Erika Cecchin
Clinical Pharmacology & Therapeutics. 2018;
[Pubmed] | [DOI]
22 PHEDRA: using real-world data to analyze treatment patterns and ibrutinib effectiveness in hematological malignancies
Jamie Garside,Nollaig Healy,Hervé Besson,Ruben Hermans,Finlay MacDougall,Damien Lestelle,Joris Diels,Wafae Iraqi
Journal of Comparative Effectiveness Research. 2017;
[Pubmed] | [DOI]
23 Evaluating beneficial drug effects in a non-interventional setting: a review of effectiveness studies based on Swedish Prescribed Drug Register data
Susanna M. Wallerstedt,Mikael Hoffmann
British Journal of Clinical Pharmacology. 2017;
[Pubmed] | [DOI]
24 Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom
Richa Sinha,William Ken Redekop
Clinical Lymphoma Myeloma and Leukemia. 2017;
[Pubmed] | [DOI]
25 Real-world cardiovascular disease burden in patients with atherosclerotic cardiovascular disease: a comprehensive systematic literature review
Dasha Cherepanov,Tanya G.K. Bentley,Wendy Hsiao,Pin Xiang,Frank O’Neill,Yi Qian,Nicole Yurgin,David Beenhouwer
Current Medical Research and Opinion. 2017; : 1
[Pubmed] | [DOI]
26 Dual Therapy Appears Superior to Monotherapy for Low-Income Individuals With Newly Diagnosed Type 2 Diabetes
Elizabeth M. Vaughan,Craig A. Johnston,David J. Hyman,Daphne C. Hernandez,Vagish Hemmige,John P. Foreyt
Journal of Primary Care & Community Health. 2017; 8(4): 305
[Pubmed] | [DOI]
27 Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World
Yaimarelis Saumell,Lizet Sanchez,Sandra González,Ramón Ortiz,Edadny Medina,Yaima Galán,Agustin Lage
Advances in Therapy. 2017; 34(12): 2638
[Pubmed] | [DOI]
28 Inventory of real world data sources in Parkinson’s disease
Audrey Tanguy,Linus Jönsson,Lianna Ishihara
BMC Neurology. 2017; 17(1)
[Pubmed] | [DOI]
29 Grass pollen sublingual immunotherapy tablets provide long-term relief of grass pollen-associated allergic rhinitis and reduce the risk of asthma: findings from a retrospective, real-world database subanalysis
Philippe Devillier,Ulrich Wahn,Stefan Zielen,Joachim Heinrich
Expert Review of Clinical Immunology. 2017; : 1
[Pubmed] | [DOI]
30 Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients
Dong Ji,Guo-Feng Chen,Cheng Wang,Yu-Dong Wang,Qing Shao,Bing Li,Jun Zhao,Shao-Li You,Jin-Hua Hu,Jia-Liang Liu,Xiao-Xia Niu,Jing Chen,Lei Lu,Vanessa Wu,George Lau
Hepatology International. 2016;
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed2157    
    Printed49    
    Emailed1    
    PDF Downloaded505    
    Comments [Add]    
    Cited by others 30    

Recommend this journal